The discovery of small molecule chemical probes of Bcl-X(L) and Mcl-1.

A tetrahydroaminoquinoline-based library was generated with the goals of finding small molecule modulators of protein-protein interactions. Several library members as well as other related intermediates were tested for their ability to bind to Bcl-X(L) and Mcl-1 by in silico and (15)N NMR studies. The NMR study led to the identification of the tetrahydroaminoquinoline-based nude scaffold, 7 as a weak binder (K(d)=200 microM for Bcl-X(L) and K(d)=300 microM for Mcl-1) to both proteins. Using this scaffold as the starting material, we then synthesized a focused library of only 9 derivatives by applying the principles of a fragment-based approach. All these derivatives were then tested by NMR and this led to the discovery of a novel, small molecule (MIPRALDEN, 17) as a binder to Mcl-1 and Bcl-X(L) (K(D)=25 and 70 microM). This finding is novel because to our knowledge there are not many small molecules known in the literature that bind to Mcl-1.

[1]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[2]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[3]  Imran Siddiqi,et al.  Solvated Interaction Energy (SIE) for Scoring Protein-Ligand Binding Affinities, 1. Exploring the Parameter Space , 2007, J. Chem. Inf. Model..

[4]  Erinna F. Lee,et al.  Structural insights into the degradation of Mcl-1 induced by BH3 domains , 2007, Proceedings of the National Academy of Sciences.

[5]  S. Richardson,et al.  Solution Structure of Prosurvival Mcl-1 and Characterization of Its Binding by Proapoptotic BH3-only Ligands* , 2005, Journal of Biological Chemistry.

[6]  John Calvin Reed,et al.  Apoptosis-based therapies , 2002, Nature Reviews Drug Discovery.

[7]  D. Hockenbery,et al.  Small-molecule inhibitors of Bcl-2. , 2006, Current opinion in investigational drugs.

[8]  D. Andrews,et al.  Development of dimeric modulators for anti-apoptotic Bcl-2 proteins. , 2008, Bioorganic & medicinal chemistry letters.

[9]  P. Dent,et al.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.

[10]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[11]  K. Gehring,et al.  Solution Structure of Human BCL-w , 2003, Journal of Biological Chemistry.

[12]  P. Hajduk,et al.  Puzzling through fragment-based drug design , 2006, Nature chemical biology.

[13]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature reviews. Drug discovery.

[14]  A. Letai.  BCL-2: found bound and drugged! , 2005, Trends in Molecular Medicine.

[15]  H. Abaan,et al.  Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. , 2006, Journal of medicinal chemistry.

[16]  C. Tse,et al.  Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. , 2007, Cancer research.

[17]  Laurent Bélec,et al.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis , 2007, Proceedings of the National Academy of Sciences.

[18]  David C Fry,et al.  Protein-protein interactions as targets for small molecule drug discovery. , 2006, Biopolymers.

[19]  K. Schulze-Osthoff,et al.  Apoptosis-based therapies and drug targets , 2005, Cell Death and Differentiation.

[20]  L. Walensky.  BCL-2 in the crosshairs: tipping the balance of life and death , 2006, Cell Death and Differentiation.

[21]  Stephen W. Fesik,et al.  Promoting apoptosis as a strategy for cancer drug discovery , 2005, Nature Reviews Cancer.

[22]  Mary K Joseph,et al.  Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. , 2007, Journal of medicinal chemistry.

[23]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[24]  D. Erlanson.  Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.

[25]  L. Scorrano,et al.  Laying the foundations of programmed cell death , 2006, Cell Death and Differentiation.

[26]  Christopher I. Bayly,et al.  Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validation , 2002, J. Comput. Chem..

[27]  P. Hajduk,et al.  Privileged molecules for protein binding identified from NMR-based screening. , 2000, Journal of medicinal chemistry.

[28]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[29]  Erinna F. Lee,et al.  Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family , 2007, Cell Death and Differentiation.